Scott Rocklage: Biomedical Industry Veteran Helping 5AM Venture To Grow

Dr. Scott M. Rocklage is a managing partner at the investment company 5AM Venture Management LLC. He joined the company in 2003 as a venture partner and was promoted to his current position one year later. Dr. Rocklage brings a great deal of knowledge and experience to his role at 5AM Venture Management.

He has an extensive scientific background, years of healthcare management experience and a track record for exemplary strategic leadership. Dr. Rocklage has been involved in the biomedical and pharmaceutical industry for over 25 years.

After graduating from UC Berkley with a bachelor’s degree in chemistry, Scott Rocklage went on to the Massachusetts Institute of Technology where he earned a Ph.D. in Chemistry. While at MIT, Rocklage did research in the laboratory of Richard R. Schrock, the Nobel Prize winner.

Dr. Rocklage has also published important writing in over 100 peer-reviewed publications. He also has more than 30 U.S. patents where he is listed as either inventor or co-inventor. Plus, Dr. Rocklage has played an important role in getting Food and Drug Administration approval for several drugs. Learn more about Scott Rocklage: http://chemistry.mit.edu/scott-rocklage-phd-2-and-his-wife-patty-are-celebrated-their-major-gift and https://www.linkedin.com/in/scott-rocklage-66aa7a12a

Beginning in 1990, Dr. Scott Rocklage has held leadership positions with an impressive array of pharmaceutical companies. He was Nycomed Salutar, Inc. president and CEO and president and board chairman of Nycomed Interventional.

Dr. Rocklage also served as Cubist Pharmaceuticals founding CEO and president and was a director at several companies including Pulmatrix, Inc., EPIRUS Biopharmaceuticals, MDS Proteomics, Inc., Relypsa, Inc., Vaccines Inc., Protana Inc. and Achaogen, Inc. Dr. Scott Rocklage was also executive chairman of Semprus BioSciences Corporation and Miikana Therapeutics Inc., president and CEO of Amersham Health, Novira Therapeutics, Inc. chairman, board chairman of Rennovia Inc. and Cidara Therapeutics and is on the boards of Kinestral and the Whitehead Institute.

In addition to all the leadership positions Dr. Rocklage has held, he also spent time working in several research and development positions with Catalytica Pharmaceuticals and Salutar.

Currently based in 5AM Ventures’ office in Boston, Massachusetts, Dr. Scott Rocklage has been very instrumental in helping the company to identify and invest in a number of very successful biomedical companies.

Read more: Scott Racklage | Bloomberg

Comments are closed.